Fiebersyndrome: Kinderwunsch und Schwangerschaft

Zusammenfassung

Autoinflammatorische Erkrankungen treten meist in der Kindheit oder den jungen Erwachsenenjahren auf und nehmen daher auch Einfluss auf Kinderwunsch/Reproduktion der Patienten. Die Datenlage für Fertilität und Schwangerschaftsausgang und -komplikationen ist weiterhin sehr eingeschränkt, soll in diesem Artikel aber zusammengefasst werden. Grundsätzlich gilt auch für Patienten mit autoinflammatorischen Erkrankungen derselbe Grundsatz wie für andere Patienten mit chronisch entzündlichen Erkrankungen: Um ein möglichst geringes Risiko für Mutter und Kind zu ermöglichen, sollten die Patienten vor einer Schwangerschaft (ideal: 6 Monate), unter einer mit einer Schwangerschaft zu vereinbarenden Medikation, in stabiler Remission sein.

Abstract

Autoinflammatory diseases mostly occur during childhood or adolescence and therefore influence aspects of reproduction and pregnancy. Published data of pregnancy outcomes and complications is still very rare. This article tries to summarise the existing evidence. In general, the treatment of patients with autoinflammatory diseases should follow the same principle that is used in patients with other chronic inflammatory diseases: Patients should be in stable remission (ideally 6 months) with a medication that is compatible with pregnancy.

Schlüsselwörter

Schwangerschaft - Fertilität - Familiäres Mittelmeerfieber - M. Still - Cryopyrin assoziierte Periodische Syndrome

Key words

pregnancy - fertility - familiar Mediterranean fever - adult onset still syndrome - crypyrin associated periodic syndrome

• Literatur

• 1 Sohar E, Gafni J, Pras M et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43: 227-253
• 2 Mijatovic V, Hompes PG, Wouters MG. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol 2003; 108: 171-176
• 3 Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62: 916-919
• 4 Ehrenfeld M, Brzezinski A, Levy M et al. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987; 94: 1186-1191
• 5 Mont’Alverne AR, Pereira RM, Yamakami LY et al. Reduced ovarian reserve in patients with takayasu arteritis. J Rheumatol 2014; 41: 2055-2059
• 6 Henes M, Froeschlin J, Taran FA et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behcet’s disease and spondyloarthritis on anti-Mullerian hormone levels. Rheumatology (Oxford) 2015; 54: 1709-1712
• 7 Lawrenz B, Henes J, Henes M et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011; 20: 1193-1197
• 8 Mont’Alverne AR, Yamakami LY, Goncalves CR et al. Diminished ovarian reserve in Behcet’s disease patients. Clin Rheumatol 2015; 34: 179-183
• 9 de Souza FH, da Silva CA, Yamakami LY et al. Reduced ovarian reserve in patients with adult polymyositis. Clin Rheumatol 2015; 34: 1795-1799
• 10 Henes MRK, Igney-Oertel A, Taran F et al. Anti-Muellerian hormone levels are not reduced in patients with adult auto-inflammatory diseases compared to healthy controls. Scan J Rheum 2016 accepted
• 11 Sahin A, Karakus S, Durmaz Y et al. Evaluation of ovarian reserve with anti-mullerian hormone in familial mediterranean fever. Int J Rheumatol 2015; 2015: 380354
• 12 Ben-Chetrit E, Backenroth R, Haimov-Kochman R et al. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann Rheum Dis 1998; 57: 259-260
• 13 Haimov-Kochman R, Prus D, Ben-Chetrit E. Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod 2001; 16: 1218-1220
• 14 Haimov-Kochman R, Ben-Chetrit E. The effect of colchicine treatment on sperm production and function: a review. Hum Reprod 1998; 13: 360-362
• 15 Yasar O, Iskender C, Kaymak O et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med 2014; 27: 733-736
• 16 Ofir D, Levy A, Wiznitzer A et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008; 141: 115-118
• 17 Ben-Chetrit E, Ben-Chetrit A, Berkun Y et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified?. Arthritis Care Res (Hoboken) 2010; 62: 143-148
• 18 Amoura Z, Schermann JM, Wechsler B et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol 1994; 21: 383
• 19 Diav-Citrin O, Shechtman S, Schwartz V et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010; 203: 144 e1-e6
• 20 Rabinovitch O, Zemer D, Kukia E et al. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 28: 245-246
• 21 Berkenstadt M, Weisz B, Cuckle H et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol 2005; 193: 1513-1516
• 22 Herscovici T, Merlob P, Stahl B et al. Colchicine use during breastfeeding. Breastfeed Med 2015; 10: 92-95
• 23 McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297
• 24 Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140: 784-790
• 25 Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93: 91-99
• 26 Lequerre T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308
• 27 Pouchot J, Arlet JB. Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol 2012; 26: 477-487
• 28 Gerfaud-Valentin M, Hot A, Huissoud C et al. Adult-onset Still’s disease and pregnancy: about ten cases and review of the literature. Rheumatol Int 2014; 34: 867-871
• 29 Le Loet X, Daragon A, Duval C et al. Adult onset Still’s disease and pregnancy. J Rheumatol 1993; 20: 1158-1161
• 30 Mok MY, Lo Y, Leung PY et al. Pregnancy outcome in patients with adult onset Still’s disease. J Rheumatol 2004; 31: 2307-2309
• 31 Yamamoto M, Tabeya T, Suzuki C et al. Adult-onset Still’s disease in pregnancy. Mod Rheumatol 2012; 22: 163-165
• 32 Liozon E, Ly K, Aubard Y et al. Intravenous immunoglobulins for adult Still’s disease and pregnancy. Rheumatology (Oxford) 1999; 38: 1024-1025
• 33 Vignes S, Wechsler B, Amoura Z et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998; 16: 295-298
• 34 Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol 2011; 29: 1021-1023
• 35 Izumi Y, Mori T, Matsuo M et al. Leukocytapheresis (LCAP) for treating refractory adult-onset Still’s disease (AOSD). Mod Rheumatol 2012; 22: 483-487
• 36 Kanekura T, Terasaki K, Higashi Y et al. Improvement of adult Still’s disease with granulocyte and monocyte adsorption apheresis. Clin Exp Dermatol 2004; 29: 410-412
• 37 Odai T, Isozaki T, Kasama T et al. Therapeutic efficacy of leukocytapheresis in a pregnant woman with refractory adult-onset still’s disease. Intern Med 2015; 54: 2261-2266
• 38 Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142: 1591-1597
• 39 Tran TA, Kone-Paut I, Marie I et al. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum 2012; 42: 327-331
• 40 Chang Z, Spong CY, Jesus AA et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 2014; 66: 3227-3232
• 41 ter Haar NM, Oswald M, Jeyaratnam J et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74: 1636-1644